IL13 and COVID-19: Of note, treatment with the therapeutic compounds commonly administered to acute COVID-19 patients (the JAK inhibitors baricitinib, ruxolitinib and tofacitinib) were able to restore normal cell viability, proliferation and neurogenesis by targeting the effects of IL12 and IL13.